ArticleJournal of immunology (Baltimore, Md. : 1950)2015
The inducible costimulator augments Tc17 cell responses to self and tumor tissue.
Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- The immunology of vitiligo.Nature reviews. Immunology · 2026Review
- CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting.Bioorganic & medicinal chemistry letters · 2025Review
- Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment.Cancer immunology research · 2025Article
- Integrated multiomics revealed adenosine signaling predict immunotherapy response and regulate tumor ecosystem of melanoma.Human genomics · 2024Article
- Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade.Biomarker research · 2023Article
- Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma.Journal for immunotherapy of cancer · 2023Article
- Adoptive transfer of IL-4 reprogrammed Tc17 cells elicits anti-tumour immunity through functional plasticity.Immunology · 2022Article
- B cells imprint adoptively transferred CD8Journal for immunotherapy of cancer · 2022Article
- Transcriptome profile and clinical characterization of ICOS expression in gliomas.Frontiers in oncology · 2022Article
- Myron Gordon Award paper: Microbes, T-cell diversity and pigmentation.Pigment cell & melanoma research · 2021Review
- ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.Blood advances · 2020Article
- The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.ESMO open · 2020Review
- Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.Pigment cell & melanoma research · 2019Article
- Age-Associated Heterogeneity of Ty21a-Induced T Cell Responses to HLA-E RestrictedFrontiers in immunology · 2019Article
- CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.Frontiers in immunology · 2018Review
- β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.JCI insight · 2017Article
- Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.JCI insight · 2017Article
- Immunoregulatory functions of VISTA.Immunological reviews · 2017Review
- The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.Journal of immunology research and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
The inducible costimulator (ICOS) plays a key role in the development of Th17 cells, but its role in the development and antitumor activity of IL-17-producing CD8(+) T cells (Tc17) remains unknown. We found that ICOS costimulation was important for the functional maintenance, but not differentiation, of Tc17 cells in vitro. Blocking the ICOS pathway using an antagonist mAb or by using recipient mice genetically deficient in the ICOS ligand reduced the antitumor activity of adoptively transferred Tc17 cells. Conversely, activating Tc17 cells with an ICOS agonist in vitro enhanced their capacity to eradicate melanoma and induce autoimmune vitiligo when infused into mice. However, ICOS stimulation did not augment the antitumor activity of IL-2 expanded T cells. Additional investigation revealed that ICOS stimulation not only increased IL-2Rα, CXCR3, and IL-23R expression on Tc17 cells, but also dampened their expression of suppressive molecule CD39. Although Tc17 cells activated with an ICOS agonist cosecreted heightened IL-17A, IL-9, and IFN-γ, their therapeutic effectiveness was critically dependent on IFN-γ production. Depletion of IL-17A and IL-9 had little impact on antitumor Tc17 cells activated with an ICOS agonist. Collectively, our work reveals that the ICOS pathway potentiates the antitumor activity of adoptively transferred Tc17 cells. This work has major implications for the design of vaccine, Ab and cell-based therapies for autoimmunity, infectious disease, and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.